Pharmatimes Media Ltd

Pharmatimes Media Ltd company information, Employees & Contact Information

Kickstarting healthcare conversations. PharmaTimes Magazine is the leading pharmaceutical magazine for senior decision makers in the pharma and healthcare industries. It is recognised for its wide-ranging coverage of the key developments facing this fast-paced sector, and its analytical, independent content. PharmaTimes Magazine has a dedicated staff of writers and editors who have many years' experience in writing and editing copy for pharma and healthcare readers in national newspapers, magazines and online. PharmaTimes Magazine readers range from pharmaceutical executives, to healthcare professionals (chief pharmacists, medicines management, academic health science networks and NHS commissioners), to government ministers. Available in print and digital versions, on Newsstand and Google Play. PharmaTimes Competitions provide business partners and sponsors with unique access to senior decision makers, in order to gain real insight into the business challenges faced by pharma customers. This allows partners and sponsors the opportunity to build relationships and formulate service offerings around customer needs.

Company Details

Employees
14
Founded
-
Address
Mansard House, Church Road,little Bookham,united Kingdom
Phone
4402072406999
Email
su****@****mes.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Leatherhead, Surrey
Looking for a particular Pharmatimes Media Ltd employee's phone or email?

Pharmatimes Media Ltd Questions

News

Domain Therapeutics begins patient dosing in phase 1/2 trial of DT-7012 - PharmaTimes

Domain Therapeutics begins patient dosing in phase 1/2 trial of DT-7012 PharmaTimes

Fezolinetant shows real-world promise for menopause symptoms - PharmaTimes

Fezolinetant shows real-world promise for menopause symptoms PharmaTimes

Scotland approves new treatment option for multiple myeloma patients - PharmaTimes

Scotland approves new treatment option for multiple myeloma patients PharmaTimes

PharmaTimes Clinical Researcher of the Year – The Americas Awards - PharmaTimes

PharmaTimes Clinical Researcher of the Year – The Americas Awards PharmaTimes

Anne White to retire as head of Lilly Neuroscience after three decades at company - PharmaTimes

Anne White to retire as head of Lilly Neuroscience after three decades at company PharmaTimes

Orexa reports promising results in post-operative recovery trial - PharmaTimes

Orexa reports promising results in post-operative recovery trial PharmaTimes

2025 PharmaTimes Clinical Researcher of the Year - PharmaTimes

2025 PharmaTimes Clinical Researcher of the Year PharmaTimes

Teva and Fosun Pharma partner on early-stage oncology drug - PharmaTimes

Teva and Fosun Pharma partner on early-stage oncology drug PharmaTimes

Eisai data shows sustained benefit of lecanemab in early Alzheimer’s disease - PharmaTimes

Eisai data shows sustained benefit of lecanemab in early Alzheimer’s disease PharmaTimes

Sever Pharma expands work on ketamine implant with Silo Pharma - PharmaTimes

Sever Pharma expands work on ketamine implant with Silo Pharma PharmaTimes

Porosome Therapeutics unveils breakthrough Alzheimer’s research - PharmaTimes

Porosome Therapeutics unveils breakthrough Alzheimer’s research PharmaTimes

North Star shows promise in phase 2 thyroid trial - PharmaTimes

North Star shows promise in phase 2 thyroid trial PharmaTimes

Actithera closes $75.5m Series A to advance radioligand therapy platform - PharmaTimes

Actithera closes $75.5m Series A to advance radioligand therapy platform PharmaTimes

Experts call for urgent action to improve Alzheimer’s diagnosis across Europe - PharmaTimes

Experts call for urgent action to improve Alzheimer’s diagnosis across Europe PharmaTimes

Patient puzzle - PharmaTimes

Patient puzzle PharmaTimes

Kling Bio partners with Sanofi to accelerate antibody discovery - PharmaTimes

Kling Bio partners with Sanofi to accelerate antibody discovery PharmaTimes

Massalia Therapeutics launches to advance novel treatments for complex conditions - PharmaTimes

Massalia Therapeutics launches to advance novel treatments for complex conditions PharmaTimes

PharmaTimes Clinical Researcher of the Year – The Americas - PharmaTimes

PharmaTimes Clinical Researcher of the Year – The Americas PharmaTimes

Migraine takes the spotlight at European Parliament - PharmaTimes

Migraine takes the spotlight at European Parliament PharmaTimes

NICE backs AstraZeneca’s dual immunotherapy for advanced liver cancer - PharmaTimes

NICE backs AstraZeneca’s dual immunotherapy for advanced liver cancer PharmaTimes

Investigational treatment shows promise for aggressive multiple myeloma - PharmaTimes

Investigational treatment shows promise for aggressive multiple myeloma PharmaTimes

Herantis Pharma doses final cohort in phase 1b trial of HER-096 for Parkinson’s disease - PharmaTimes

Herantis Pharma doses final cohort in phase 1b trial of HER-096 for Parkinson’s disease PharmaTimes

Ionis shares phase 3 results for olezarsen in moderate hypertriglyceridaemia - PharmaTimes

Ionis shares phase 3 results for olezarsen in moderate hypertriglyceridaemia PharmaTimes

SkyCell and Microsoft partner to improve pharma supply chains - PharmaTimes

SkyCell and Microsoft partner to improve pharma supply chains PharmaTimes

NHS England secures access to new cystic fibrosis treatment ALYFTREK - PharmaTimes

NHS England secures access to new cystic fibrosis treatment ALYFTREK PharmaTimes

Nice recommends first AI medical device for skin cancer diagnosis in the NHS - PharmaTimes

Nice recommends first AI medical device for skin cancer diagnosis in the NHS PharmaTimes

AlzeCure presents phase 2 data on ACD440 at NeuPSIG 2025 - PharmaTimes

AlzeCure presents phase 2 data on ACD440 at NeuPSIG 2025 PharmaTimes

MHRA approves first oral treatment for hereditary angioedema attacks - PharmaTimes

MHRA approves first oral treatment for hereditary angioedema attacks PharmaTimes

Amgen’s Tepezza granted marketing authorisation in the UK - PharmaTimes

Amgen’s Tepezza granted marketing authorisation in the UK PharmaTimes

TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform - PharmaTimes

TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform PharmaTimes

Xeltis prepares for commercial launch after strong aXess trial results - PharmaTimes

Xeltis prepares for commercial launch after strong aXess trial results PharmaTimes

Eisai unveils promising phase 1b data for narcolepsy drug E2086 - PharmaTimes

Eisai unveils promising phase 1b data for narcolepsy drug E2086 PharmaTimes

Ogsiveo approved in EU for treatment of desmoid tumors - PharmaTimes

Ogsiveo approved in EU for treatment of desmoid tumors PharmaTimes

Lab-grown lung cancer cells show potential to revolutionise treatment - PharmaTimes

Lab-grown lung cancer cells show potential to revolutionise treatment PharmaTimes

Nxera and Cancer Research UK begin phase 2a trial of HTL0039732 - PharmaTimes

Nxera and Cancer Research UK begin phase 2a trial of HTL0039732 PharmaTimes

FDA approves Amneal’s self-administered migraine drug Brekiya - PharmaTimes

FDA approves Amneal’s self-administered migraine drug Brekiya PharmaTimes

Grifols clinical trial shows positive results for post-polio patients - PharmaTimes

Grifols clinical trial shows positive results for post-polio patients PharmaTimes

MHRA approves prostate cancer imaging agent trofolastat - PharmaTimes

MHRA approves prostate cancer imaging agent trofolastat PharmaTimes

Vedanta’s ulcerative colitis candidate misses phase 2 efficacy target - PharmaTimes

Vedanta’s ulcerative colitis candidate misses phase 2 efficacy target PharmaTimes

iOnctura starts randomised phase 1/2 trial in lung cancer treatment - PharmaTimes

iOnctura starts randomised phase 1/2 trial in lung cancer treatment PharmaTimes

Datapharm collaborates with VIDAL to improve medicines information access in France - PharmaTimes

Datapharm collaborates with VIDAL to improve medicines information access in France PharmaTimes

MHRA grants Promising Innovative Medicine designation to UCB’s DoxTM for TK2d - PharmaTimes

MHRA grants Promising Innovative Medicine designation to UCB’s DoxTM for TK2d PharmaTimes

FDA approves LEQEMBI IQLIK for maintenance dosing in early Alzheimer’s disease - PharmaTimes

FDA approves LEQEMBI IQLIK for maintenance dosing in early Alzheimer’s disease PharmaTimes

Agomab announces positive phase 2a interim results for AGMB-129 - PharmaTimes

Agomab announces positive phase 2a interim results for AGMB-129 PharmaTimes

Proximie and HistoSonics partner to transform liver tumour treatment in US - PharmaTimes

Proximie and HistoSonics partner to transform liver tumour treatment in US PharmaTimes

Chiesi partners with Wirral Primary Care to improve COPD detection - PharmaTimes

Chiesi partners with Wirral Primary Care to improve COPD detection PharmaTimes

MHRA approves guselkumab for Crohn’s disease and ulcerative colitis - PharmaTimes

MHRA approves guselkumab for Crohn’s disease and ulcerative colitis PharmaTimes

Seaport Therapeutics begins phase 2b trial of GlyphAllo for major depression - PharmaTimes

Seaport Therapeutics begins phase 2b trial of GlyphAllo for major depression PharmaTimes

Linear Diagnostics awarded £1m to develop rapid STI test - PharmaTimes

Linear Diagnostics awarded £1m to develop rapid STI test PharmaTimes

Vorasidenib approved in UK for treating IDH-mutant brain tumours - PharmaTimes

Vorasidenib approved in UK for treating IDH-mutant brain tumours PharmaTimes

NHS ConfedExpo 2025: a platform for change in UK health and care - PharmaTimes

NHS ConfedExpo 2025: a platform for change in UK health and care PharmaTimes

Rishi Sunak joins Prostate Cancer Research as an ambassador - PharmaTimes

Rishi Sunak joins Prostate Cancer Research as an ambassador PharmaTimes

Capvaxive shows strong immune response in children at risk of pneumococcal disease - PharmaTimes

Capvaxive shows strong immune response in children at risk of pneumococcal disease PharmaTimes

Qureight and Avalyn launch strategic partnership in pulmonary fibrosis - PharmaTimes

Qureight and Avalyn launch strategic partnership in pulmonary fibrosis PharmaTimes

Microbiotica unveils new data on MB097 at AACR IO meeting - PharmaTimes

Microbiotica unveils new data on MB097 at AACR IO meeting PharmaTimes

Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol - PharmaTimes

Tris Pharma announces positive results from ALLEVIATE-1 trial of cebranopadol PharmaTimes

AlzeCure’s NeuroRestore ACD856 to be presented at AD/PD 2025 - PharmaTimes

AlzeCure’s NeuroRestore ACD856 to be presented at AD/PD 2025 PharmaTimes

Apiary invests in life sciences marketing specialist performance-io - PharmaTimes

Apiary invests in life sciences marketing specialist performance-io PharmaTimes

BiomX phage therapy shows potent effect in cystic fibrosis trial - PharmaTimes

BiomX phage therapy shows potent effect in cystic fibrosis trial PharmaTimes

Lilly and UK Government launch £85 million obesity care innovation programme - PharmaTimes

Lilly and UK Government launch £85 million obesity care innovation programme PharmaTimes

MindMed begins phase 3 study of MM120 for anxiety disorder - PharmaTimes

MindMed begins phase 3 study of MM120 for anxiety disorder PharmaTimes

Pfizer’s Talzenna therapy accepted for use within NHS Scotland - PharmaTimes

Pfizer’s Talzenna therapy accepted for use within NHS Scotland PharmaTimes

Tagomics secures £860k grant for colorectal cancer test - PharmaTimes

Tagomics secures £860k grant for colorectal cancer test PharmaTimes

Gilead and LEO Pharma partner to develop oral STAT6 program - PharmaTimes

Gilead and LEO Pharma partner to develop oral STAT6 program PharmaTimes

Guselkumab receives CHMP backing for subcutaneous induction in ulcerative colitis - PharmaTimes

Guselkumab receives CHMP backing for subcutaneous induction in ulcerative colitis PharmaTimes

Bimekizumab shows lasting efficacy at EULAR 2025 - PharmaTimes

Bimekizumab shows lasting efficacy at EULAR 2025 PharmaTimes

Careology and Entia join forces to transform cancer care - PharmaTimes

Careology and Entia join forces to transform cancer care PharmaTimes

Levicept presents new LEVI-04 data at EULAR - PharmaTimes

Levicept presents new LEVI-04 data at EULAR PharmaTimes

New prostate cancer test cuts biopsies by 50% in US - PharmaTimes

New prostate cancer test cuts biopsies by 50% in US PharmaTimes

Amgen’s lung cancer treatment gets conditional approval - PharmaTimes

Amgen’s lung cancer treatment gets conditional approval PharmaTimes

AI set to revolutionise pharmaceutical R&D says GlobalData - PharmaTimes

AI set to revolutionise pharmaceutical R&D says GlobalData PharmaTimes

Cambridge scientists develop ‘super test’ for prostate cancer - PharmaTimes

Cambridge scientists develop ‘super test’ for prostate cancer PharmaTimes

Angelini Ventures co-leads Series A financing in Neumirna Therapeutics - PharmaTimes

Angelini Ventures co-leads Series A financing in Neumirna Therapeutics PharmaTimes

Gedeon Richter launches Nalvee in UK to expand HRT options for menopause - PharmaTimes

Gedeon Richter launches Nalvee in UK to expand HRT options for menopause PharmaTimes

Johnson & Johnson submits application for subcutaneous Rybrevant dosing - PharmaTimes

Johnson & Johnson submits application for subcutaneous Rybrevant dosing PharmaTimes

Novartis gene therapy set to enhance SMA treatment - PharmaTimes

Novartis gene therapy set to enhance SMA treatment PharmaTimes

Amlenetug receives FDA Fast Track Designation - PharmaTimes

Amlenetug receives FDA Fast Track Designation PharmaTimes

New injection offers hope for asthma and COPD attacks - PharmaTimes

New injection offers hope for asthma and COPD attacks PharmaTimes

UK regulator warns against buying weight-loss medicines without prescription - PharmaTimes

UK regulator warns against buying weight-loss medicines without prescription PharmaTimes

Vedanta Biosciences reveals Phase 2 VE303 results - PharmaTimes

Vedanta Biosciences reveals Phase 2 VE303 results PharmaTimes

Anocca announces authorisation pancreatic cancer trial - PharmaTimes

Anocca announces authorisation pancreatic cancer trial PharmaTimes

European Commission approves ustekinumab for paediatric Crohn’s disease - PharmaTimes

European Commission approves ustekinumab for paediatric Crohn’s disease PharmaTimes

Cambridge Cognition highlights positive Cantab results - PharmaTimes

Cambridge Cognition highlights positive Cantab results PharmaTimes

Capgemini unveils AI breakthrough to boost bioeconomy - PharmaTimes

Capgemini unveils AI breakthrough to boost bioeconomy PharmaTimes

4 ways AI is shaping the future of Life Sciences - PharmaTimes

4 ways AI is shaping the future of Life Sciences PharmaTimes

WHO report highlights resurgence of tuberculosis - PharmaTimes

WHO report highlights resurgence of tuberculosis PharmaTimes

ICON and LEO Pharma join forces on clinical trial mission - PharmaTimes

ICON and LEO Pharma join forces on clinical trial mission PharmaTimes

NICE gives green light for MSD’s Keytruda - PharmaTimes

NICE gives green light for MSD’s Keytruda PharmaTimes

Silent plight - PharmaTimes

Silent plight PharmaTimes

UK study reveals persistent challenges in heart health and cardiovascular diseases - PharmaTimes

UK study reveals persistent challenges in heart health and cardiovascular diseases PharmaTimes

Chemical reaction - PharmaTimes

Chemical reaction PharmaTimes

Remote patient monitoring: the future of healthcare? - PharmaTimes

Remote patient monitoring: the future of healthcare? PharmaTimes

Study suggests COVID-19 vaccination lowers incidence of arterial thromboses - PharmaTimes

Study suggests COVID-19 vaccination lowers incidence of arterial thromboses PharmaTimes

Women in Healthcare: Shairose Ebrahim - PharmaTimes

Women in Healthcare: Shairose Ebrahim PharmaTimes

University of Liverpool launches new biotech spin-out company Galytx - PharmaTimes

University of Liverpool launches new biotech spin-out company Galytx PharmaTimes

Oxford researchers launch HIV vaccine trial - PharmaTimes

Oxford researchers launch HIV vaccine trial PharmaTimes

Gavin Spencer - PharmaTimes

Gavin Spencer PharmaTimes

Leading with Purpose - PharmaTimes

Leading with Purpose PharmaTimes

MIT’s AI model can detect Parkinson’s by tracking breathing patterns - PharmaTimes

MIT’s AI model can detect Parkinson’s by tracking breathing patterns PharmaTimes

NICE, Cochrane to collaborate on delivery of ‘living’ recommendations - PharmaTimes

NICE, Cochrane to collaborate on delivery of ‘living’ recommendations PharmaTimes

Top Pharmatimes Media Ltd Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant